DUPAN-2 antigen measurement method, measurement reagent and measurement kit

Abstract

To provide a measuring method, a measuring reagent, and a measuring kit that can eliminate a difference between measured values when different types of standard substances are measured or reduce the difference between the measured values to accurately measure a DUPAN-2 antigen in a sample.SOLUTION: A method for measuring a DUPAN-2 antigen in a sample includes preparing a mixed solution including an aqueous medium, the DUPAN-2 antigen in the sample, a first antibody coupled to an insoluble carrier and recognizing the DUPAN-2 antigen, and a second antibody recognizing the DUPAN-2 antigen. In the mixed solution, an amount of the first antibody recognizing the DUPAN-2 antigen is three times by weight or more and 100 times by weight or less an amount of the second antibody recognizing the DUPAN-2 antigen.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a method for measuring DUPAN-2 antigen, a measuring reagent and a measuring kit, and a method for producing an insoluble carrier to which a first antibody that recognizes DUPAN-2 antigen is bound, which is included in the measuring reagent and measuring kit for DUPAN-2 antigen. [Background technology]

[0002] The monoclonal antibody DUPAN-2 was produced using human pancreatic cancer cultured cells HPAF as an immunogen, and has been reported to react with a mucin-like protein (antigen) produced at high rates by pancreatic cancer cells (Non-Patent Documents 1 and 2). This antigen, known as the DUPAN-2 antigen, is used as a cancer marker for pancreatic cancer, biliary tract cancer, and other cancers.

[0003] As methods for measuring the DUPAN-2 antigen, competition radioimmunoassay (Non-Patent Document 1) and Enzyme-Linked ImmunoSorbent Assay (Patent Document 1) have been reported. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2019 / 189874 Brochure [Non-patent literature]

[0005] [Non-Patent Document 1] Metzgar et al., “Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma,” Proceedings of the National Academy of Sciences of the United States of America, 1984, Vol. 81, pp. 5242-5246. [Non-patent document 2] Sakurabayashi et al., "Study on pancreatic cancer-associated glycoprotein antigen, DU-PAN-2 I. Basic examination in enzyme immunoassay and distribution of measured values ​​in healthy subjects," Clinical Pathology, 1986, Vol. 34, pp. 705-710 Summary of the Invention [Problem to be solved by the invention]

[0006] When measuring DUPAN-2 antigen in a sample, the concentration of the DUPAN-2 antigen in the sample is determined based on the measurement value of a reference material. Reference materials used for measuring DUPAN-2 antigen include DUPAN-2 antigen derived from ascites fluid of human pancreatic cancer patients and DUPAN-2 antigen derived from HPAF human pancreatic cancer cultured cells. However, when different types of reference materials are measured, the measured values ​​can differ even though the reference materials have the same concentration. Therefore, the concentration of DUPAN-2 antigen in a sample can vary depending on the type of reference material used. Therefore, there is a need for a measurement method and measurement reagent that can eliminate or reduce the difference in measurement values ​​when measuring different types of reference materials and accurately measure DUPAN-2 antigen in a sample. The present invention aims to provide a measurement method, a measurement reagent, and a measurement kit that can accurately measure DUPAN-2 antigen in a sample. Another object of the present invention is to provide a method for producing an insoluble carrier to which a first antibody that recognizes DUPAN-2 antigen is bound, which is included in the measurement reagent and measurement kit. [Means for solving the problem]

[0007] As a result of intensive research to solve the above-mentioned problems, the inventors discovered that when reacting DUPAN-2 antigen in a sample with a first antibody that recognizes DUPAN-2 antigen and is bound to an insoluble carrier, and a second antibody that recognizes DUPAN-2 antigen, by mixing the first antibody that recognizes DUPAN-2 antigen and the second antibody that recognizes DUPAN-2 antigen in a predetermined ratio, it is possible to eliminate or reduce the difference in measurement values ​​when measuring different types of standard substances, and to accurately measure DUPAN-2 antigen in a sample, thereby completing the invention disclosed herein.

[0008] That is, in one aspect, the present disclosure provides the following. [1] A method for detecting DUPAN-2 antigen comprising preparing a mixture containing an aqueous medium, a DUPAN-2 antigen in a sample, a first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, and a second antibody that recognizes the DUPAN-2 antigen; A method for measuring DUPAN-2 antigen in a sample, wherein the amount of the first antibody that recognizes the DUPAN-2 antigen in the mixture is at least 3 times and at most 100 times by weight the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0009] [2] (1) reacting a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both bound to an insoluble carrier, with the DUPAN-2 antigen in a sample in an aqueous medium to form an immune complex on the insoluble carrier, the immune complex consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (2) measuring the immune complex produced in step (1); Including, A method for measuring DUPAN-2 antigen in a sample, wherein in the reaction solution of step (1), the amount of the first antibody that recognizes the DUPAN-2 antigen is at least 3 times and not more than 100 times the weight of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0010] [3] (1) A step of reacting a first antibody that recognizes the DUPAN-2 antigen, which is bound to an insoluble carrier, with the DUPAN-2 antigen in a sample in an aqueous medium, to form an immune complex 1 on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen; (2) reacting a second antibody that recognizes the DUPAN-2 antigen with the immune complex 1 produced in step (1) in an aqueous medium to produce, on the insoluble carrier, an immune complex 2 consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (3) measuring the immune complex 2 produced in step (2); Including, A method for measuring DUPAN-2 antigen in a sample, wherein in step (2), the amount of a first antibody that recognizes the DUPAN-2 antigen is at least 3 times and not more than 100 times by weight the amount of a second antibody that recognizes the DUPAN-2 antigen.

[0011] [4] (1) adding a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier, to a sample containing the DUPAN-2 antigen; (2) reacting the DUPAN-2 antigen in an aqueous medium with a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to the insoluble carrier, to form an immune complex on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (3) measuring the immune complex produced in step (2); Including, A method for measuring DUPAN-2 antigen in a sample, wherein in step (1), the amount of a first antibody that recognizes the DUPAN-2 antigen added is at least 3 times by weight and not more than 100 times by weight the amount of a second antibody that recognizes the DUPAN-2 antigen added.

[0012] [5] (1) adding a first antibody that recognizes the DUPAN-2 antigen, bound to an insoluble carrier, to a sample containing the DUPAN-2 antigen; (2) reacting the DUPAN-2 antigen with a first antibody that recognizes the DUPAN-2 antigen and that is bound to the insoluble carrier in an aqueous medium to form an immune complex 1 on the insoluble carrier, the immune complex consisting of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen; (3) adding a second antibody that recognizes the DUPAN-2 antigen to the immune complex 1 produced in step (2); (4) reacting a second antibody that recognizes the DUPAN-2 antigen with the immune complex 1 produced in step (2) in an aqueous medium to produce an immune complex 2 on the insoluble carrier, the immune complex 2 consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (5) measuring the immune complex 2 produced in step (4); Including, A method for measuring DUPAN-2 antigen in a sample, wherein the amount of a first antibody that recognizes the DUPAN-2 antigen added in step (1) is at least 3 times and not more than 100 times the weight of the amount of a second antibody that recognizes the DUPAN-2 antigen added in step (3). [6] The method according to any one of [1] to [5], wherein a label is bound to a second antibody that recognizes the DUPAN-2 antigen. [7] The method according to [6], wherein the label is alkaline phosphatase.

[0013] [8] An insoluble carrier having a first antibody that recognizes the DUPAN-2 antigen bound thereto, and a second antibody that recognizes the DUPAN-2 antigen; A reagent for measuring DUPAN-2 antigen in a sample, wherein the amount of a first antibody that recognizes the DUPAN-2 antigen is 3 to 100 times by weight the amount of a second antibody that recognizes the DUPAN-2 antigen.

[0014] [9] A first reagent comprising an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen, and a second reagent comprising a second antibody that recognizes the DUPAN-2 antigen, A kit for measuring DUPAN-2 antigen in a sample, in which the amount of a first antibody that recognizes the DUPAN-2 antigen in the first reagent is at least 3 times and not more than 100 times the weight of the amount of a second antibody that recognizes the DUPAN-2 antigen in the second reagent.

[0015]

[10] A method for producing an insoluble carrier to which a first antibody that recognizes the DUPAN-2 antigen is bound in the reagent according to [8], comprising: (1) adding an aqueous medium containing a first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier; and (2) binding a first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier; A method comprising:

[11] The method according to

[10] , wherein in step (1), the concentration of the first antibody that recognizes the DUPAN-2 antigen added is 6 μg / mL or more and 30 μg / mL or less.

[0016]

[12] A method for producing an insoluble carrier having a first antibody that recognizes the DUPAN-2 antigen bound thereto in the kit according to [9], comprising: (1) adding an aqueous medium containing a first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier; and (2) binding a first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier; A method comprising:

[13] The method according to

[12] , wherein in step (1), the concentration of the first antibody that recognizes the DUPAN-2 antigen added is 6 μg / mL or more and 30 μg / mL or less. [Effects of the Invention]

[0017] According to the present disclosure, even when different types of standard substances are measured, the difference in the measurement values ​​of each standard substance is eliminated or reduced, thereby providing a method, reagent, and kit that can accurately measure DUPAN-2 antigen in a sample. DETAILED DESCRIPTION OF THE INVENTION

[0018] Hereinafter, embodiments for carrying out the present disclosure will be described in detail. Note that the embodiments described below are examples of typical embodiments of the present disclosure, and should not be construed as narrowing the scope of the disclosure. Note that numerical ranges indicated using "to" indicate ranges that include the numerical values ​​before and after "to" as the minimum and maximum values, respectively. Furthermore, when multiple substances corresponding to each component are present in the solution, the amount of each component in the solution refers to the total amount of the multiple substances present in the reagent, unless otherwise specified. In the present disclosure, "% (w / v)" means the percentage of mass (g) based on volume (100 mL).

[0019] In the present disclosure, when an antibody is expressed as "binding to," "reacting with," or "recognizing" a DUPAN-2 antigen, these terms include the meanings commonly used in the field of the present disclosure and are used interchangeably. Methods for confirming the "binding" of an antibody to a DUPAN-2 antigen include competitive ELISA, sandwich ELISA, and methods utilizing the principle of surface plasmon resonance, which are well known to those skilled in the art.

[0020] "Aqueous medium" Examples of aqueous media in the present disclosure include deionized water, distilled water, and buffer solutions, with buffer solutions being preferred. Examples of buffering agents used to prepare buffer solutions include acetate buffer solutions and Good's buffer solutions. One type of buffering agent may be used alone, or two or more types may be used in combination. The aqueous medium may contain salts, metal ions, sugars, proteins, surfactants, and the like. Examples of salts include lithium chloride, sodium chloride, potassium chloride, calcium chloride, and magnesium chloride. Examples of metal ions include sodium ions, magnesium ions, manganese ions, and zinc ions. Examples of sugars include mannitol and sorbitol. Examples of proteins include bovine serum albumin (hereinafter referred to as BSA). Examples of surfactants include anionic surfactants, cationic surfactants, amphoteric surfactants, and nonionic surfactants.

[0021] "sample" The sample in the present disclosure is not particularly limited as long as it is a sample that may contain the DUPAN-2 antigen, and examples thereof include any one or more biological samples selected from the group consisting of whole blood, plasma, serum, urine, ascites, cerebrospinal fluid, saliva, amniotic fluid, urine, sweat, and pancreatic juice, and preferably includes whole blood, plasma, serum, ascites, etc. Furthermore, the sample may be a cell lysate of cultured human pancreatic cancer cells HPAF, or a culture supernatant obtained when cultured human pancreatic cancer cells HPAF. The sample in the present disclosure may be DUPAN-2 antigen contained in an aqueous medium, such as DUPAN-2 antigen diluted with phosphate-buffered saline (10 mmol / L phosphate buffer containing 0.15 mol / L sodium chloride, pH 7.2, hereinafter referred to as PBS). DUPAN-2 antigen purified from the biological sample, cell lysate, or culture supernatant can be used as the DUPAN-2 antigen contained in the aqueous medium.

[0022] "Insoluble carrier" In the present disclosure, the insoluble carrier is not particularly limited as long as it enables the measurement method for DUPAN-2 antigen of the present disclosure or is usable in the measurement reagent or measurement kit of the present disclosure, and examples thereof include glass slides, ELISA plates (microtiter plates), beads, latex particles, magnetic particles, filters, films, membranes, etc. Examples of materials for the insoluble carrier include those made of inorganic substrates, polysaccharide substrates, polymer substrates, etc., such as glass, silicon, ceramic, cellulose, nitrocellulose, nylon, polycarbonate, polyethylene, polypropylene, polystyrene, polyethylene terephthalate, and polyurethane.

[0023] "DUPAN-2 antigen" The DUPAN-2 antigen in the present disclosure refers to a mucin-like protein (glycoprotein) to which the monoclonal antibody "DUPAN-2" (Metzgar et al., "Antigens of Human Pancreatic Adenocarcinoma Cells Defined by Murine Monoclonal Antibodies", CANCER RESEARCH (1982), 42:601-608) binds, a glycan to which the monoclonal antibody "DUPAN-2" binds, or a peptide containing such a glycan. Specifically, the DUPAN-2 antigen refers to the sialyl Lewis C sugar chain reportedly bound by the monoclonal antibody "DUPAN-2" (Kawa et al., "Epitope Analysis of Span-1 and DUPAN-2 using Synthesized Glycoconjugates Sialyllact-N-Fucopentaose II and Sialyllact-N-Tetraose", Pancreas (1994), 9 (6):692-697), a protein having such a sugar chain, or a peptide having such a sugar chain. The DUPAN-2 antigen can be obtained from the ascites of a human pancreatic cancer patient or from the culture supernatant of human pancreatic cancer cultured cells HPAF. Human pancreatic cancer cultured cells HPAF are available from the American Type Culture Collection (ATCC) under the name "HPAF-II."

[0024] "Antibody that recognizes the DUPAN-2 antigen" In the present disclosure, an antibody that recognizes the DUPAN-2 antigen (a first antibody that recognizes the DUPAN-2 antigen, a second antibody that recognizes the DUPAN-2 antigen) refers to an antibody that recognizes the sialyl Lewis C of the DUPAN-2 antigen and is capable of binding to the DUPAN-2 antigen.

[0025] The antibody that recognizes the DUPAN-2 antigen may be a mouse antibody, rat antibody, rabbit antibody, human antibody, humanized antibody, or chimeric antibody, or may be an antibody derived from another species. Furthermore, the antibody that recognizes the DUPAN-2 antigen may be any class of immunoglobulin molecule (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0026] Antibodies that recognize the DUPAN-2 antigen include monoclonal antibodies, polyclonal antibodies, dimers, multimers, etc., with monoclonal antibodies being preferred from the standpoints of homogeneity and stability.

[0027] In the present disclosure, an antibody that recognizes the DUPAN-2 antigen may be an antibody fragment. An antibody fragment refers to a portion of an antibody that recognizes the DUPAN-2 antigen, and includes the variable domain of the antibody or at least the antigen-binding region. Examples of antibody fragments in the present disclosure include Fab, Fab', F(ab')2, Fv fragments, linear antibodies, single-chain antibodies (scFv), sc(Fv)2, Fab3, domain antibodies (dAb), diabodies, triabodies, tetrabodies, and minibodies. An "Fv fragment" is the smallest antibody fragment and includes the complete antigen-recognition region and antigen-binding region.

[0028] The first antibody that recognizes the DUPAN-2 antigen of the present disclosure and the second antibody that recognizes the DUPAN-2 antigen may bind to the same or different sites on the DUPAN-2 antigen. Furthermore, the first antibody that recognizes the DUPAN-2 antigen and the second antibody that recognizes the DUPAN-2 antigen may be the same antibody or different antibodies.

[0029] Antibodies that recognize the DUPAN-2 antigen of the present disclosure can be obtained by conventional antibody production methods using the DUPAN-2 antigen or cancer cells that produce the DUPAN-2 antigen as an immunogen. For example, antibody-producing cells obtained by immunizing an animal with the immunogen are fused with myeloma cells to produce cells (hybridomas), and the monoclonal antibodies produced by the hybridomas can be obtained. Examples of monoclonal antibodies that recognize the DUPAN-2 antigen include the monoclonal antibody "DUPAN-2" (Metzgar et al., "Antigens of Human Pancreatic Adenocarcinoma Cells Defined by Murine Monoclonal Antibodies," CANCER RESEARCH (1982), 42:601-608). In the present disclosure, the monoclonal antibody DUPAN-2 is also referred to as the "DUPAN-2 antibody."

[0030] "First antibody that recognizes the DUPAN-2 antigen, bound to an insoluble carrier" The method for binding the first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier is not particularly limited as long as it enables the measurement method for the DUPAN-2 antigen of the present disclosure or is usable in the measurement reagent or measurement kit of the present disclosure, and examples include physical adsorption and chemical bonding. Examples of physical adsorption include electrostatic bonding, hydrogen bonding, and hydrophobic bonding. Examples of chemical bonding include covalent bonding and coordinate bonding.

[0031] The first antibody that recognizes the DUPAN-2 antigen may be bound to the insoluble carrier directly or indirectly using the aforementioned physical adsorption and / or chemical binding. Indirect binding methods include a method in which the first antibody that recognizes the DUPAN-2 antigen is bound to the insoluble carrier using the specific binding between a pair of affinity substances such as biotin and avidin (avidin, streptavidin, neutravidin, etc.), and a method in which the first antibody is bound to the insoluble carrier by a covalent bond via a linker.

[0032] When a set of affinity substances is used, a first antibody that recognizes the DUPAN-2 antigen bound to one of the affinity substances (A) of the set can be bound to an insoluble carrier to produce a first antibody that recognizes the DUPAN-2 antigen bound to an insoluble carrier.

[0033] Examples of combinations of Aa include the following combinations. Combinations of biotin and avidins (avidin, neutravidin, streptavidin, etc.); Combinations of avidins (avidin, neutravidin, streptavidin, etc.) with biotin; A combination of the Fc region of a first antibody that recognizes the DUPAN-2 antigen and an antibody that binds to the Fc region.

[0034] Examples of linkers include molecules that can covalently bond both functional groups on the surface of the insoluble carrier and functional groups carried by the first antibody that recognizes the DUPAN-2 antigen. For example, a molecule that simultaneously has a first reactive group that can react with the functional group carried by the first antibody that recognizes the DUPAN-2 antigen and a second reactive group that can react with the functional group on the surface of the insoluble carrier, where the first reactive group and the second reactive group are different groups, is preferably used. Examples of functional groups carried by the first antibody that recognizes the DUPAN-2 antigen and functional groups carried on the surface of the insoluble carrier include carboxyl groups, amino groups, glycidyl groups, sulfhydryl groups, hydroxyl groups, amide groups, imino groups, N-hydroxysuccinyl groups, and maleimide groups. Examples of reactive groups in the linker include allyl azide, carbodiimide, hydrazide, aldehyde, hydroxymethylphosphine, imide ester, isocyanate, maleimide, N-hydroxysuccinimide ester, pentafluorophenyl (PFP) ester, psoralen, pyridyl disulfide, and vinyl sulfone.

[0035] "Method for measuring DUPAN-2 antigen in a sample" One embodiment of the method for measuring DUPAN-2 antigen in a sample in the present disclosure is a method for measuring DUPAN-2 antigen, which includes preparing a mixture containing an aqueous medium, the DUPAN-2 antigen in the sample, a first antibody that recognizes the DUPAN-2 antigen bound to an insoluble carrier, and a second antibody that recognizes the DUPAN-2 antigen.

[0036] After preparing a mixture containing an aqueous medium, the DUPAN-2 antigen in the sample, a first antibody that recognizes the DUPAN-2 antigen bound to an insoluble carrier, and a second antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen in the sample can be measured by performing the following steps. (1) reacting a DUPAN-2 antigen with a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier, to form an immune complex on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (2) A step of measuring the immune complex produced in step (1).

[0037] Furthermore, after step (2), the concentration of DUPAN-2 antigen in the sample can also be determined by carrying out the following steps (3) and (4). (3) performing steps (1) and (2) using DUPAN-2 antigen of known concentration as a sample to prepare a calibration curve showing the relationship between the DUPAN-2 antigen concentration and the measured value; (4) A step of determining the concentration of DUPAN-2 antigen in the sample from the calibration curve prepared in step (3) and the measured value obtained by the measurement in step (2).

[0038] Examples of DUPAN-2 antigen of known concentration include DUPAN-2 antigen derived from ascites of a human pancreatic cancer patient (hereinafter simply referred to as "DUPAN-2 antigen derived from ascites") or a DUPAN-2 antigen solution obtained by diluting DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF with PBS. Multiple concentrations of DUPAN-2 antigen of known concentration may be prepared.

[0039] The concentration of DUPAN-2 antigen in a known concentration of DUPAN-2 antigen is not particularly limited as long as it is a concentration that allows measurement of DUPAN-2 antigen, and may be 10 U / mL or more, 20 U / mL or more, 30 U / mL or more, 40 U / mL or more, 50 U / mL or more, 60 U / mL or more, 70 U / mL or more, 80 U / mL or more, 90 U / mL or more, or 100 U / mL or more. Furthermore, the concentration of DUPAN-2 antigen in a DUPAN-2 antigen of known concentration may be 200 U / mL or less, 300 U / mL or less, 350 U / mL or less, 400 U / mL or less, 500 U / mL or less, 600 U / mL or less, 700 U / mL or less, 800 U / mL or less, 900 U / mL or less, 1000 U / mL or less, 1100 U / mL or less, 1200 U / mL or less, 1400 U / mL or less, 1600 U / mL or less, 1800 U / mL or less, 2000 U / mL or less, 3000 U / mL or less, 4000 U / mL or less, 5000 U / mL or less, 6000 U / mL or less, 7000 U / mL or less, 8000 U / mL or less, 9000 U / mL or less, 10000 U / mL or less, or 15000 U / mL or less. The concentration unit of DUPAN-2 antigen, "U / mL," is defined as "the concentration of DUPAN-2 antigen contained in the serum of a specific pancreatic cancer patient, measured by competitive radioimmunoassay, is 1000 U / mL" (Metzgar et al., "Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma," Proceedings of the National Academy of Sciences of the United States of America, 1984, Vol. 81, pp. 5242-5246).

[0040] The above values ​​can be freely combined, and may be, for example, 10 U / mL to 10,000 U / mL, 20 U / mL to 5,000 U / mL, 30 U / mL to 1,600 U / mL, 40 U / mL to 400 U / mL, or 40 U / mL to 350 U / mL. In the present disclosure, any numerical range obtained by combining any numerical value selected from the examples of upper and lower limits for a certain concentration is also considered to be exemplified in the present disclosure. The same applies to other numerical values ​​such as weight multiple, molar equivalent multiple, temperature, and time.

[0041] A washing step can be performed before the step (2). The washing solution used to wash the insoluble carrier is not particularly limited as long as it allows measurement of the DUPAN-2 antigen, and examples thereof include PBS and PBS containing a surfactant. Examples of surfactants include nonionic surfactants such as Tween 20.

[0042] In preparing the mixture, the DUPAN-2 antigen in the sample, the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, and the second antibody that recognizes the DUPAN-2 antigen may be mixed in any order. For example, the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier may be mixed with the DUPAN-2 antigen in the sample and the second antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen in the sample may be mixed with the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier and the second antibody that recognizes the DUPAN-2 antigen, or the DUPAN-2 antigen in the sample may be mixed with the second antibody that recognizes the DUPAN-2 antigen and the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier.

[0043] In the mixture, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 times or more, 2.7 times or more, 2.8 times or more, 2.9 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, or 9 times or more by weight of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in the mixture, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 times by weight or less, 12 times by weight or less, 13 times by weight or less, 14 times by weight or less, 15 times by weight or less, 20 times by weight or less, 25 times by weight or less, 30 times by weight or less, 35 times by weight or less, 40 times by weight or less, 45 times by weight or less, 50 times by weight or less, 60 times by weight or less, 70 times by weight or less, 80 times by weight or less, 90 times by weight or less, 100 times by weight or less, 150 times by weight or less, or 200 times by weight or less of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0044] The above values ​​can be freely combined. For example, in the mixed solution, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 to 200 times, 2.8 to 150 times, 3 to 100 times, 3 to 30 times, 5 to 30 times, or 5 to 10 times the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0045] In the mixture, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 molar equivalents or more, 2.7 molar equivalents or more, 2.8 molar equivalents or more, 2.9 molar equivalents or more, 3 molar equivalents or more, 4 molar equivalents or more, 5 molar equivalents or more, 6 molar equivalents or more, 7 molar equivalents or more, 8 molar equivalents or more, or 9 molar equivalents or more of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in the mixture, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 molar equivalents or less, 12 molar equivalents or less, 13 molar equivalents or less, 14 molar equivalents or less, 15 molar equivalents or less, 20 molar equivalents or less, 25 molar equivalents or less, 30 molar equivalents or less, 35 molar equivalents or less, 40 molar equivalents or less, 45 molar equivalents or less, 50 molar equivalents or less, 60 molar equivalents or less, 70 molar equivalents or less, 80 molar equivalents or less, 90 molar equivalents or less, 100 molar equivalents or less, 150 molar equivalents or less, or 200 molar equivalents or less of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0046] The above numerical values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen in the mixed solution may be 2.6 to 200 molar equivalents, 2.8 to 150 molar equivalents, 3 to 100 molar equivalents, 3 to 30 molar equivalents, 5 to 30 molar equivalents, or 5 to 10 molar equivalents, relative to the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0047] The concentration of the insoluble carrier in the mixture is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 mg / mL or more, 0.002 mg / mL or more, 0.003 mg / mL or more, 0.004 mg / mL or more, 0.005 mg / mL or more, 0.01 mg / mL or more, 0.02 mg / mL or more, 0.03 mg / mL or more, 0.04 mg / mL or more, 0.05 mg / mL or more, 0.06 mg / mL or more, 0.07 mg / mL or more, 0.08 mg / mL or more, 0.09 mg / mL or more, 0.1 mg / mL or more, 0.2 mg / mL or more, 0.3 mg / mL or more, 0.4 mg / mL or more, or 0.5 mg / mL or more. In addition, the concentration of the insoluble carrier in the mixture may be 0.6 mg / mL or less, 0.7 mg / mL or less, 0.8 mg / mL or less, 0.9 mg / mL or less, 1 mg / mL or less, 2 mg / mL or less, 3 mg / mL or less, 4 mg / mL or less, 5 mg / mL or less, 6 mg / mL or less, 7 mg / mL or less, 8 mg / mL or less, 9 mg / mL or less, or 10 mg / mL or less.

[0048] The above values ​​can be freely combined. For example, the concentration of the insoluble carrier in the mixed solution may be 0.003 mg / mL to 10 mg / mL, 0.01 mg / mL to 3 mg / mL, or 0.05 mg / mL to 1 mg / mL.

[0049] The concentration of the first antibody that binds to the DUPAN-2 antigen in the mixture is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, mL or more, 0.3 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. Furthermore, the concentration of the first antibody that binds to the DUPAN-2 antigen in the mixture may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0050] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen in the mixed solution may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0051] The concentration of the second antibody that binds to the DUPAN-2 antigen in the mixture is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 μg / mL or more, 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.33 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, or 0.9 μg / mL or more. Furthermore, the concentration of the second antibody that binds to the DUPAN-2 antigen in the mixture may be 1 μg / mL or less, 2 μg / mL or less, 3 μg / mL or less, 4 μg / mL or less, 5 μg / mL or less, 6 μg / mL or less, 7 μg / mL or less, 7.5 μg / mL or less, 8 μg / mL or less, 9 μg / mL or less, 10 μg / mL or less, 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0052] The above values ​​can be freely combined. For example, the concentration of the second antibody that binds to the DUPAN-2 antigen in the mixed solution may be 0.01 μg / mL to 100 μg / mL, 0.03 μg / mL to 30 μg / mL, 0.1 μg / mL to 20 μg / mL, or 0.1 μg / mL to 1 μg / mL. In this specification, the amount or concentration of a second antibody that binds to the DUPAN-2 antigen means not only the amount or concentration of the second antibody itself, but also the amount or concentration of a labeled antibody bound to the second antibody and a label described below.

[0053] The concentration of DUPAN-2 antigen in the mixed solution is not particularly limited as long as it is a concentration that allows measurement of the DUPAN-2 antigen, and may be 1 U / mL to 1000 U / mL, 2 U / mL to 500 U / mL, 3 U / mL to 160 U / mL, 4 U / mL to 160 U / mL, 4 U / mL to 40 U / mL, or 6 U / mL to 35 U / mL.

[0054] Another embodiment of the method of measuring DUPAN-2 antigen in a sample according to the present disclosure comprises: (1) reacting a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier, with the DUPAN-2 antigen in a sample in an aqueous medium to form an immune complex on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (2) measuring the immune complex produced in step (1); A method for measuring DUPAN-2 antigen in a sample, comprising:

[0055] Furthermore, after step (2), the concentration of DUPAN-2 antigen in the sample can also be determined by carrying out the following steps (3) and (4). (3) performing steps (1) and (2) using DUPAN-2 antigen of known concentration as a sample to prepare a calibration curve showing the relationship between the DUPAN-2 antigen concentration and the measured value; (4) A step of determining the concentration of DUPAN-2 antigen in the sample from the calibration curve prepared in step (3) and the measured value obtained by the measurement in step (2).

[0056] Examples of DUPAN-2 antigen of known concentration include DUPAN-2 antigen solutions prepared by diluting DUPAN-2 antigen derived from ascites or DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF with PBS. Multiple concentrations of DUPAN-2 antigen of known concentration may be prepared.

[0057] The concentration of DUPAN-2 antigen in the DUPAN-2 antigen of known concentration is not particularly limited as long as it is a concentration that allows measurement of the DUPAN-2 antigen, and examples thereof include the concentrations described above.

[0058] A washing step can be performed before the step (2). The washing solution used to wash the insoluble carrier is not particularly limited as long as it allows measurement of the DUPAN-2 antigen, and examples thereof include PBS and PBS containing a surfactant. Examples of the surfactant include nonionic surfactants such as Tween (registered trademark) 20.

[0059] <Process (1)> Step (1) is a step in which, in an aqueous medium, a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both bound to an insoluble carrier, are reacted with the DUPAN-2 antigen in a sample, thereby generating an immune complex on the insoluble carrier consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen.

[0060] In step (1), the reaction between the DUPAN-2 antigen and the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, and the second antibody that recognizes the DUPAN-2 antigen is not particularly limited, as long as an immune complex consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen is formed on the insoluble carrier.For example, the DUPAN-2 antigen may be reacted with the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier to form an immune complex of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen on the insoluble carrier, and then the second antibody that recognizes the DUPAN-2 antigen may be reacted, or the DUPAN-2 antigen may be mixed with the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, and then reacted. When a first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier and a second antibody that recognizes the DUPAN-2 antigen are mixed and reacted with the DUPAN-2 antigen, the order in which the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier and the second antibody that recognizes the DUPAN-2 antigen can be added may be any order. For example, the DUPAN-2 antigen in the sample and the second antibody that recognizes the DUPAN-2 antigen may be added to the first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, the first antibody that recognizes the DUPAN-2 antigen and the second antibody that recognizes the DUPAN-2 antigen may be added to the DUPAN-2 antigen in the sample, or the DUPAN-2 antigen in the sample and the first antibody that recognizes the DUPAN-2 antigen bound to an insoluble carrier may be added to the second antibody that recognizes the DUPAN-2 antigen.

[0061] Step (1) may be carried out separately into the following steps (1-1) and (1-2), and then step (2) may be carried out. (1-1) a step of reacting a first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier with the DUPAN-2 antigen in a sample in an aqueous medium, thereby forming an immune complex 1 on the insoluble carrier, the immune complex 1 consisting of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen; (1-2) reacting a second antibody that recognizes the DUPAN-2 antigen with the immune complex 1 produced in step (1) in an aqueous medium to produce, on the insoluble carrier, an immune complex 2 consisting of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (2) measuring the immune complex 2 produced in step (1-2);

[0062] A washing step can be provided between the steps (1-1) and (1-2). A washing step can also be provided between the steps (1-2) and (2). The washing solution used to wash the insoluble carrier is not particularly limited as long as it allows measurement of the DUPAN-2 antigen, and examples thereof include PBS and PBS containing a surfactant. Examples of surfactants include nonionic surfactants such as Tween 20.

[0063] In steps (1), (1-1) and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 times or more, 2.7 times or more, 2.8 times or more, 2.9 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, or 9 times or more by weight of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in steps (1), (1-1) and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 times by weight or less, 12 times by weight or less, 13 times by weight or less, 14 times by weight or less, 15 times by weight or less, 20 times by weight or less, 25 times by weight or less, 30 times by weight or less, 35 times by weight or less, 40 times by weight or less, 45 times by weight or less, 50 times by weight or less, 60 times by weight or less, 70 times by weight or less, 80 times by weight or less, 90 times by weight or less, 100 times by weight or less, 150 times by weight or less, or 200 times by weight or less of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0064] The above values ​​can be freely combined. For example, in steps (1), (1-1), and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 to 200 times, 2.8 to 150 times, 3 to 100 times, 3 to 30 times, 5 to 30 times, or 5 to 10 times the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0065] In steps (1), (1-1) and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 molar equivalents or more, 2.7 molar equivalents or more, 2.8 molar equivalents or more, 2.9 molar equivalents or more, 3 molar equivalents or more, 4 molar equivalents or more, 5 molar equivalents or more, 6 molar equivalents or more, 7 molar equivalents or more, 8 molar equivalents or more, or 9 molar equivalents or more of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in steps (1), (1-1) and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 molar equivalents or less, 12 molar equivalents or less, 13 molar equivalents or less, 14 molar equivalents or less, 15 molar equivalents or less, 20 molar equivalents or less, 25 molar equivalents or less, 30 molar equivalents or less, 35 molar equivalents or less, 40 molar equivalents or less, 45 molar equivalents or less, 50 molar equivalents or less, 60 molar equivalents or less, 70 molar equivalents or less, 80 molar equivalents or less, 90 molar equivalents or less, 100 molar equivalents or less, 150 molar equivalents or less, or 200 molar equivalents or less of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0066] The above numerical values ​​can be freely combined. For example, in steps (1), (1-1), and (1-2), the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 to 200 molar equivalents, 2.8 to 150 molar equivalents, 3 to 100 molar equivalents, 3 to 30 molar equivalents, 5 to 30 molar equivalents, or 5 to 10 molar equivalents, relative to the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0067] The concentration of the insoluble carrier in steps (1) and (1-1) is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 mg / mL or more, 0.002 mg / mL or more, 0.003 mg / mL or more, 0.004 mg / mL or more, 0.005 mg / mL or more, 0.01 mg / mL or more, 0.02 mg / mL or more, 0.03 mg / mL or more, 0.04 mg / mL or more, 0.05 mg / mL or more, 0.06 mg / mL or more, 0.07 mg / mL or more, 0.08 mg / mL or more, 0.09 mg / mL or more, 0.1 mg / mL or more, 0.2 mg / mL or more, 0.3 mg / mL or more, 0.4 mg / mL or more, or 0.5 mg / mL or more. The concentration of the insoluble carrier in step (1) and step (1-1) may be 0.6 mg / mL or less, 0.7 mg / mL or less, 0.8 mg / mL or less, 0.9 mg / mL or less, 1 mg / mL or less, 2 mg / mL or less, 3 mg / mL or less, 4 mg / mL or less, 5 mg / mL or less, 6 mg / mL or less, 7 mg / mL or less, 8 mg / mL or less, 9 mg / mL or less, or 10 mg / mL or less.

[0068] The above values ​​can be freely combined. For example, the concentration of the insoluble carrier in the steps (1) and (1-1) may be 0.003 mg / mL to 10 mg / mL, 0.01 mg / mL to 3 mg / mL, or 0.05 mg / mL to 1 mg / mL.

[0069] The amount of the first antibody that recognizes the DUPAN-2 antigen in steps (1), (1-1) and (1-2) is not particularly limited as long as it is an amount that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.5 ng or more, 1 ng or more, 1.5 ng or more, 2 ng or more, 2.5 ng or more, 3 ng or more, 3.5 ng or more, 4 ng or more, 4.5 ng or more, 5 ng or more, 10 ng or more, 15 ng or more, 20 ng or more, 25 ng or more, 30 ng or more, 35 ng or more, 40 ng or more, 45 ng or more, 50 ng or more, 100 ng or more, 150 ng or more, 200 ng or more, 250 ng or more, 300 ng or more, 350 ng or more, 400 ng or more, 450 ng or more, or 500 ng or more. Furthermore, the amount of the first antibody recognizing the DUPAN-2 antigen in steps (1), (1-1) and (1-2) may be 550 ng or less, 600 ng or less, 650 ng or less, 700 ng or less, 750 ng or less, 800 ng or less, 850 ng or less, 900 ng or less, 950 ng or less, 1 μg or less, 1.5 μg or less, 2 μg or less, 2.5 μg or less, or 5 μg or less.

[0070] The above values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen in steps (1), (1-1), and (1-2) may be 0.5 ng to 5 μg, 5 ng to 1.5 μg, 150 ng to 1 μg, 300 ng to 1 μg, or 500 ng to 1 μg.

[0071] The concentration of the first antibody that recognizes the DUPAN-2 antigen in the steps (1), (1-1), and (1-2) is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. Furthermore, the concentration of the first antibody that binds to the DUPAN-2 antigen in steps (1), (1-1) and (1-2) may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0072] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen in steps (1), (1-1), and (1-2) may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0073] The amount of the second antibody that recognizes the DUPAN-2 antigen in steps (1) and (1-2) is not particularly limited as long as it is an amount that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.1 ng or more, 1 ng or more, 2 ng or more, 3 ng or more, 4 ng or more, 5 ng or more, 6 ng or more, 7 ng or more, 8 ng or more, 9 ng or more, 10 ng or more, 20 ng or more, 30 ng or more, 40 ng or more, 50 ng or more, 60 ng or more, 70 ng or more, 80 ng or more, or 90 ng or more. Furthermore, the amount of the second antibody that recognizes the DUPAN-2 antigen in steps (1) and (1-2) may be 100 ng or less, 200 ng or less, 300 ng or less, 400 ng or less, 500 ng or less, 600 ng or less, 700 ng or less, 800 ng or less, 900 ng or less, 1 μg or less, 1.1 μg or less, 1.2 μg or less, 1.3 μg or less, 1.4 μg or less, 1.5 μg or less, 1.6 μg or less, 1.7 μg or less, 1.8 μg or less, 1.9 μg or less, 2 μg or less, 3 μg or less, 4 μg or less, 5 μg or less, or 10 μg or less.

[0074] The above values ​​can be freely combined. For example, the amount of the second antibody that recognizes the DUPAN-2 antigen in steps (1) and (1-2) may be 1 ng to 10 μg, 3 ng to 3 μg, 10 ng to 2 μg, or 10 ng to 100 ng.

[0075] The concentration of the second antibody that binds to the DUPAN-2 antigen in steps (1) and (1-2) is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 μg / mL or more, 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.33 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, or 0.9 μg / mL or more. Furthermore, the concentration of the second antibody that binds to the DUPAN-2 antigen in steps (1) and (1-2) may be 1 μg / mL or less, 2 μg / mL or less, 3 μg / mL or less, 4 μg / mL or less, 5 μg / mL or less, 6 μg / mL or less, 7 μg / mL or less, 7.5 μg / mL or less, 8 μg / mL or less, 9 μg / mL or less, 10 μg / mL or less, 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0076] The above values ​​can be freely combined. For example, the concentration of the second antibody that binds to the DUPAN-2 antigen in steps (1) and (1-2) may be 0.01 μg / mL to 100 μg / mL, 0.03 μg / mL to 30 μg / mL, 0.1 μg / mL to 20 μg / mL, or 0.1 μg / mL to 1 μg / mL.

[0077] The steps (1), (1-1) and (1-2) are preferably carried out in an aqueous medium, such as the aqueous medium described above. Furthermore, the steps (1), (1-1) and (1-2) may contain the above-mentioned salts, metal ions, sugars, proteins, surfactants and the like.

[0078] The reaction temperature in the steps (1), (1-1), and (1-2) is not particularly limited as long as it allows for measurement of the DUPAN-2 antigen, and is, for example, 0 to 50° C., preferably 4 to 45° C., and particularly preferably 20 to 40° C. The reaction time in the steps (1), (1-1), and (1-2) is not particularly limited as long as it allows for measurement of the DUPAN-2 antigen, and is, for example, 5 minutes to 3 hours, and preferably 10 minutes to 2 hours.

[0079] <Process (2)> In step (2), the measured value of DUPAN-2 antigen in the sample is determined by measuring the immune complex produced in step (1) or the immune complex 2 produced in step (1-2) using the following method.

[0080] [When the label is not bound to the second antibody that recognizes the DUPAN-2 antigen] The immune complex or immune complex 2 can be measured using a labeled third antibody (hereinafter referred to as the third antibody), in which a label is bound to an antibody that binds to the second antibody that recognizes the DUPAN-2 antigen. That is, the immune complex is reacted with the labeled third antibody to form a complex 3 between the immune complex or immune complex 2 and the labeled third antibody, and the label of the complex 3 is measured by the method described below, thereby measuring the amount of the immune complex produced in step (1) or the amount of immune complex 2 produced in step (1-2). Examples of the third antibody include an antibody that binds to the Fc region of the second antibody that recognizes the DUPAN-2 antigen.

[0081] The reaction temperature for the reaction between the labeled third antibody and the immune complex or immune complex 2 is not particularly limited as long as it allows for measurement of the DUPAN-2 antigen, and may be, for example, 0 to 50°C, 4 to 45°C, or 20 to 40°C. The reaction time for the reaction is not particularly limited as long as it allows for measurement of the DUPAN-2 antigen, and may be, for example, 1 minute to 4 hours, 5 minutes to 3 hours, or 10 minutes to 2 hours. The concentration of the labeled third antibody in the reaction solution is not particularly limited as long as it allows for measurement of the DUPAN-2 antigen, and may be, for example, 0.01 to 100 μg / mL, or 0.1 to 20 μg / mL.

[0082] [When a label is attached to the second antibody that recognizes the DUPAN-2 antigen] Step (2) can be carried out by measuring the immune complex or the immune complex 2 using a label. Methods for binding a label to a second antibody that recognizes the DUPAN-2 antigen are known in the art of immunoassays. For example, a label can be bound to an antibody via one or several amino acids, or via one or several amino acids and a linker. Various kits for binding labels to proteins are also commercially available.

[0083] Examples of labels include those used in conventional immunoassays, such as enzymes, radioisotopes, fluorescent substances, luminescent substances, DNA, RNA, coenzymes or substances that specifically bind to coenzymes (biotin, avidin), tags, substances that absorb in the ultraviolet to infrared region, chromogenic microparticles, fluorescent microparticles, metallic microparticles, magnetic substances, and substances that have properties as spin labeling agents.

[0084] Examples of the enzyme include alkaline phosphatase, peroxidase, galactosidase, glucuronidase, luciferase, etc. Examples of the radioisotope include: 3 H, 14 C. 35 S, 32 P, 125 P, 131Examples of fluorescent substances include FITC (fluorescein isothiocyanate) and RITC (rhodamine B isothiocyanate). Examples of luminescent substances include acridinium and its derivatives, ruthenium complex compounds, and lophine.

[0085] By detecting the signals generated from these labels, the immune complex or immune complex 2 can be measured. The method for measuring the signal generated from the label may be appropriately selected depending on the label used. When the label is a chromogenic substance, that is, a substance that absorbs light of a certain wavelength, the label can be measured by measuring absorbance using a spectrophotometer, a multiwell plate reader, or the like. When the label is a fluorescent substance, the label can be measured by measuring the fluorescence intensity using a fluorometer, a fluorescent multiwell plate reader, or the like. When the label is a luminescent substance, the label can be measured by measuring the luminescence intensity using a luminescence photometer, a luminescence multiwell plate reader, or the like. When the label is a radioisotope, the label can be measured by measuring the radioactivity using a scintillation counter, a γ-well counter, or the like. When the label is an enzyme, the label can be measured by measuring the enzyme activity, for example, by reacting the enzyme's substrate with the enzyme and measuring the product.

[0086] The measurement method according to the present disclosure may include the following addition step (A) prior to the step (1). (A) A step of adding, to the DUPAN-2 antigen in a sample in an aqueous medium, a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier.

[0087] The measurement method according to the present disclosure may include the following addition step (A1) prior to the step (1-1). (A1) A step of adding a first antibody that recognizes the DUPAN-2 antigen, bound to an insoluble carrier, to a sample containing the DUPAN-2 antigen. The step (A1) may be a step of adding a sample containing the DUPAN-2 antigen to a first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier.

[0088] The measurement method according to the present disclosure may include the following addition step (A2) prior to the step (1-2). (A2) A step of adding a second antibody that recognizes the DUPAN-2 antigen to the immune complex 1 produced in the step (1-1). The step (A2) may be a step of adding the immune complex 1 produced in the step (1-2) to a second antibody that recognizes the DUPAN-2 antigen.

[0089] In steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 2.6 times by weight or more, 2.7 times by weight or more, 2.8 times by weight or more, 2.9 times by weight or more, 3 times by weight or more, 4 times by weight or more, 5 times by weight or more, 6 times by weight or more, 7 times by weight or more, 8 times by weight or more, or 9 times by weight or more of the amount of the second antibody that recognizes the DUPAN-2 antigen added. Furthermore, in steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 10 times by weight or less, 12 times by weight or less, 13 times by weight or less, 14 times by weight or less, 15 times by weight or less, 20 times by weight or less, 25 times by weight or less, 30 times by weight or less, 35 times by weight or less, 40 times by weight or less, 45 times by weight or less, 50 times by weight or less, 60 times by weight or less, 70 times by weight or less, 80 times by weight or less, 90 times by weight or less, 100 times by weight or less, 150 times by weight or less, or 200 times by weight or less of the amount of the second antibody that recognizes the DUPAN-2 antigen added.

[0090] The above numerical values ​​can be freely combined. For example, in steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 2.6 to 200 times by weight, 2.8 to 150 times by weight, 3 to 100 times by weight, 3 to 30 times by weight, 5 to 30 times by weight, or 5 to 10 times by weight.

[0091] In steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 2.6 molar equivalents or more, 2.7 molar equivalents or more, 2.8 molar equivalents or more, 2.9 molar equivalents or more, 3 molar equivalents or more, 4 molar equivalents or more, 5 molar equivalents or more, 6 molar equivalents or more, 7 molar equivalents or more, 8 molar equivalents or more, or 9 molar equivalents or more of the amount of the second antibody that recognizes the DUPAN-2 antigen added. Furthermore, in steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 10 molar equivalents or less, 12 molar equivalents or less, 13 molar equivalents or less, 14 molar equivalents or less, 15 molar equivalents or less, 20 molar equivalents or less, 25 molar equivalents or less, 30 molar equivalents or less, 35 molar equivalents or less, 40 molar equivalents or less, 45 molar equivalents or less, 50 molar equivalents or less, 60 molar equivalents or less, 70 molar equivalents or less, 80 molar equivalents or less, 90 molar equivalents or less, 100 molar equivalents or less, 150 molar equivalents or less, or 200 molar equivalents or less of the amount of the second antibody that recognizes the DUPAN-2 antigen added.

[0092] The above numerical values ​​can be freely combined. For example, in steps (A) and (A1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 2.6 to 200 molar equivalents, 2.8 to 150 molar equivalents, 3 to 100 molar equivalents, 3 to 30 molar equivalents, 5 to 30 molar equivalents, or 5 to 10 molar equivalents, relative to the amount of the second antibody that recognizes the DUPAN-2 antigen added.

[0093] The amount of the first antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A1) is not particularly limited as long as it is an amount that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.5 ng or more, 1 ng or more, 1.5 ng or more, 2 ng or more, 2.5 ng or more, 3 ng or more, 3.5 ng or more, 4 ng or more, 4.5 ng or more, 5 ng or more, 10 ng or more, 15 ng or more, 20 ng or more, 25 ng or more, 30 ng or more, 35 ng or more, 40 ng or more, 45 ng or more, 50 ng or more, 100 ng or more, 150 ng or more, 200 ng or more, 250 ng or more, 300 ng or more, 350 ng or more, 400 ng or more, 450 ng or more, or 500 ng or more. Furthermore, the amount of the first antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A1) may be 550 ng or less, 600 ng or less, 650 ng or less, 700 ng or less, 750 ng or less, 800 ng or less, 850 ng or less, 900 ng or less, 950 ng or less, 1 μg or less, 1.5 μg or less, 2 μg or less, 2.5 μg or less, or 5 μg or less.

[0094] The above values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A1) may be 0.5 ng to 5 μg, 5 ng to 1.5 μg, 150 ng to 1 μg, 300 ng to 1 μg, or 500 ng to 1 μg.

[0095] The concentration of the first antibody that recognizes the DUPAN-2 antigen added in the steps (A) and (A1) is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. Furthermore, the concentration of the first antibody that binds to the DUPAN-2 antigen added in steps (A) and (A1) may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0096] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen added in steps (A) and (A1) may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0097] The amount of the second antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A2) is not particularly limited as long as it is an amount that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.1 ng or more, 1 ng or more, 2 ng or more, 3 ng or more, 4 ng or more, 5 ng or more, 6 ng or more, 7 ng or more, 8 ng or more, 9 ng or more, 10 ng or more, 20 ng or more, 30 ng or more, 40 ng or more, 50 ng or more, 60 ng or more, 70 ng or more, 80 ng or more, or 90 ng or more. Furthermore, the amount of the second antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A2) may be 100 ng or less, 200 ng or less, 300 ng or less, 400 ng or less, 500 ng or less, 600 ng or less, 700 ng or less, 800 ng or less, 900 ng or less, 1 μg or less, 1.1 μg or less, 1.2 μg or less, 1.3 μg or less, 1.4 μg or less, 1.5 μg or less, 1.6 μg or less, 1.7 μg or less, 1.8 μg or less, 1.9 μg or less, 2 μg or less, 3 μg or less, 4 μg or less, 5 μg or less, or 10 μg or less.

[0098] The above values ​​can be freely combined. For example, the amount of the second antibody that recognizes the DUPAN-2 antigen added in steps (A) and (A2) may be 1 ng to 10 μg, 3 ng to 3 μg, 10 ng to 2 μg, or 10 ng to 100 ng.

[0099] The concentration of the second antibody that binds to the DUPAN-2 antigen added in steps (A) and (A2) is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 μg / mL or more, 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.33 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, or 0.9 μg / mL or more. Furthermore, the concentration of the second antibody that binds to the DUPAN-2 antigen added in steps (A) and (A2) may be 1 μg / mL or less, 2 μg / mL or less, 3 μg / mL or less, 4 μg / mL or less, 5 μg / mL or less, 6 μg / mL or less, 7 μg / mL or less, 7.5 μg / mL or less, 8 μg / mL or less, 9 μg / mL or less, 10 μg / mL or less, 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0100] The above values ​​can be freely combined. For example, the concentration of the second antibody that binds to the DUPAN-2 antigen added in steps (A) and (A2) may be 0.01 μg / mL to 100 μg / mL, 0.03 μg / mL to 30 μg / mL, 0.1 μg / mL to 20 μg / mL, or 0.1 μg / mL to 1 μg / mL.

[0101] "Reagent for measuring DUPAN-2 antigen in samples" The measurement reagent for DUPAN-2 antigen in a sample of the present disclosure is a reagent used in the measurement method for DUPAN-2 antigen in a sample of the present disclosure, and one embodiment of the measurement reagent is a measurement reagent for DUPAN-2 antigen in a sample, which comprises an insoluble carrier to which a first antibody that recognizes the DUPAN-2 antigen is bound, and a second antibody that recognizes the DUPAN-2 antigen.

[0102] In the measurement reagent for DUPAN-2 antigen of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 times or more by weight, 2.7 times or more by weight, 2.8 times or more by weight, 2.9 times or more by weight, 3 times or more by weight, 4 times or more by weight, 5 times or more by weight, 6 times or more by weight, 7 times or more by weight, 8 times or more by weight, or 9 times or more by weight of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in the DUPAN-2 antigen measurement reagent of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 times or less by weight, 12 times or less by weight, 13 times or less by weight, 14 times or less by weight, 15 times or less by weight, 20 times or less by weight, 25 times or less by weight, 30 times or less by weight, 35 times or less by weight, 40 times or less by weight, 45 times or less by weight, 50 times or less by weight, 60 times or less by weight, 70 times or less by weight, 80 times or less by weight, 90 times or less by weight, 100 times or less by weight, 150 times or less by weight, or 200 times or less by weight of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0103] The above values ​​can be freely combined. For example, in the measurement reagent for DUPAN-2 antigen of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 to 200 times by weight, 2.8 to 150 times by weight, 3 to 100 times by weight, 3 to 30 times by weight, 5 to 30 times by weight, or 5 to 10 times by weight.

[0104] In the measurement reagent for DUPAN-2 antigen of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 molar equivalents or more, 2.7 molar equivalents or more, 2.8 molar equivalents or more, 2.9 molar equivalents or more, 3 molar equivalents or more, 4 molar equivalents or more, 5 molar equivalents or more, 6 molar equivalents or more, 7 molar equivalents or more, 8 molar equivalents or more, or 9 molar equivalents or more of the amount of the second antibody that recognizes the DUPAN-2 antigen. Furthermore, in the DUPAN-2 antigen measurement reagent of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 10 molar equivalents or less, 12 molar equivalents or less, 13 molar equivalents or less, 14 molar equivalents or less, 15 molar equivalents or less, 20 molar equivalents or less, 25 molar equivalents or less, 30 molar equivalents or less, 35 molar equivalents or less, 40 molar equivalents or less, 45 molar equivalents or less, 50 molar equivalents or less, 60 molar equivalents or less, 70 molar equivalents or less, 80 molar equivalents or less, 90 molar equivalents or less, 100 molar equivalents or less, 150 molar equivalents or less, or 200 molar equivalents or less of the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0105] The above numerical values ​​can be freely combined. For example, in the measurement reagent for DUPAN-2 antigen of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen may be 2.6 to 200 molar equivalents, 2.8 to 150 molar equivalents, 3 to 100 molar equivalents, 3 to 30 molar equivalents, 5 to 30 molar equivalents, or 5 to 10 molar equivalents, relative to the amount of the second antibody that recognizes the DUPAN-2 antigen.

[0106] The concentration of the insoluble carrier in the measurement reagent for the DUPAN-2 antigen of the present disclosure is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 mg / mL or more, 0.002 mg / mL or more, 0.003 mg / mL or more, 0.004 mg / mL or more, 0.005 mg / mL or more, 0.01 mg / mL or more, 0.02 mg / mL or more, 0.03 mg / mL or more, 0.04 mg / mL or more, 0.05 mg / mL or more, 0.06 mg / mL or more, 0.07 mg / mL or more, 0.08 mg / mL or more, 0.09 mg / mL or more, 0.1 mg / mL or more, 0.2 mg / mL or more, 0.3 mg / mL or more, 0.4 mg / mL or more, or 0.5 mg / mL or more. In addition, the concentration of the insoluble carrier in the measurement reagent may be 0.6 mg / mL or less, 0.7 mg / mL or less, 0.8 mg / mL or less, 0.9 mg / mL or less, 1 mg / mL or less, 2 mg / mL or less, 3 mg / mL or less, 4 mg / mL or less, 5 mg / mL or less, 6 mg / mL or less, 7 mg / mL or less, 8 mg / mL or less, 9 mg / mL or less, or 10 mg / mL or less.

[0107] The above values ​​can be freely combined. For example, the concentration of the insoluble carrier in the measurement reagent may be 0.003 mg / mL to 10 mg / mL, 0.01 mg / mL to 3 mg / mL, or 0.05 mg / mL to 1 mg / mL.

[0108] The concentration of the first antibody that recognizes the DUPAN-2 antigen in the measurement reagent for the DUPAN-2 antigen of the present disclosure is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. In addition, the concentration of the first antibody that binds to the DUPAN-2 antigen in the DUPAN-2 antigen measurement reagent of the present disclosure may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0109] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen in the measurement reagent for the DUPAN-2 antigen of the present disclosure may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0110] When the first antibody recognizing the DUPAN-2 antigen is bound to a microtiter plate and is dry and does not contain an aqueous medium, the amount of the first antibody recognizing the DUPAN-2 antigen in one well of the microtiter plate may be 0.001 μg or more, 0.01 μg or more, 0.02 μg or more, 0.03 μg or more, 0.04 μg or more, 0.05 μg or more, 0.06 μg or more, 0.07 μg or more, 0.08 μg or more, 0.09 μg or more, 0.1 μg or more, 0.2 μg or more, 0.3 μg or more, 0.4 μg or more, or 0.5 μg or more. Furthermore, the amount of the first antibody that recognizes the DUPAN-2 antigen in one well of the microtiter plate may be 0.6 μg or less, 0.7 μg or less, 0.8 μg or less, 0.9 μg or less, 1 μg or less, 2 μg or less, 3 μg or less, 4 μg or less, 5 μg or less, 6 μg or less, 7 μg or less, 7.5 μg or less, 8 μg or less, 9 μg or less, 10 μg or less, 11 μg or less, 12 μg or less, 13 μg or less, 14 μg or less, 15 μg or less, 16 μg or less, 17 μg or less, 18 μg or less, 19 μg or less, 20 μg or less, 30 μg or less, 40 μg or less, 50 μg or less, or 100 μg or less.

[0111] The above values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen in one well of the microtiter plate may be 0.01 μg to 30 μg, 0.1 μg to 10 μg, or 0.3 μg to 3 μg.

[0112] The concentration of the second antibody that binds to the DUPAN-2 antigen in the measurement reagent for the DUPAN-2 antigen of the present disclosure is not particularly limited as long as it is a concentration that enables measurement of the DUPAN-2 antigen of the present disclosure, and may be 0.001 μg / mL or more, 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.33 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, or 0.9 μg / mL or more. In addition, the concentration of the second antibody that binds to the DUPAN-2 antigen in the DUPAN-2 antigen measurement reagent of the present disclosure may be 1 μg / mL or less, 2 μg / mL or less, 3 μg / mL or less, 4 μg / mL or less, 5 μg / mL or less, 6 μg / mL or less, 7 μg / mL or less, 7.5 μg / mL or less, 8 μg / mL or less, 9 μg / mL or less, 10 μg / mL or less, 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0113] The above values ​​can be freely combined. For example, the concentration of the second antibody that binds to the DUPAN-2 antigen in the measurement reagent for the DUPAN-2 antigen of the present disclosure may be 0.01 μg / mL to 100 μg / mL, 0.03 μg / mL to 30 μg / mL, 0.1 μg / mL to 20 μg / mL, or 0.1 μg / mL to 1 μg / mL.

[0114] The measurement reagent of the present disclosure may be in a freeze-dried state or in a liquid state. When a freeze-dried measurement reagent is used, it is dissolved in an aqueous medium before measurement to form a liquid, which is then used for measurement. In the liquid measurement reagent, at least one selected from the group consisting of an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen is dissolved in an aqueous medium.

[0115] Examples of the aqueous medium include the above-mentioned aqueous media, which may contain the above-mentioned salts, metal ions, sugars, proteins, surfactants, etc.

[0116] In the measurement method of the present disclosure, "a first antibody that recognizes the DUPAN-2 antigen bound to an insoluble carrier" is synonymous with "an insoluble carrier to which a first antibody that recognizes the DUPAN-2 antigen is bound" in the measurement reagent of the present disclosure, and "an insoluble carrier to which a first antibody that recognizes the DUPAN-2 antigen is bound" in the measurement kit described below.

[0117] "DUPAN-2 antigen measurement kit in samples" The reagent for measuring DUPAN-2 antigen in a sample according to the present disclosure can also be in the form of a kit from the viewpoint of storage, transportation, distribution, etc. Preferred embodiments of the kit for measuring DUPAN-2 antigen in a sample according to the present disclosure are exemplified below. Note that in the following embodiments, the insoluble carrier bound with the first antibody that recognizes the DUPAN-2 antigen and the second antibody that recognizes the DUPAN-2 antigen can be, for example, the insoluble carrier bound with the first antibody that recognizes the DUPAN-2 antigen described above and the second antibody that recognizes the DUPAN-2 antigen.

[0118] [Measurement kit (1)] a first reagent comprising an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen; and a second reagent comprising a second antibody that recognizes the DUPAN-2 antigen. Including, a measurement kit.

[0119] The measurement kit (1) may include a third reagent containing an aqueous medium as a reagent for diluting the sample. Examples of the aqueous medium include the aqueous media described above. The aqueous medium may contain the salts, metal ions, sugars, proteins, surfactants, etc. described above. The measurement kit (1) may also include the washing solution described above, DUPAN-2 antigen of known concentrations as a standard substance, and an instruction manual describing the measurement method of the present disclosure.

[0120] In the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 2.6 times by weight or more, 2.7 times by weight or more, 2.8 times by weight or more, 2.9 times by weight or more, 3 times by weight or more, 4 times by weight or more, 5 times by weight or more, 6 times by weight or more, 7 times by weight or more, 8 times by weight or more, or 9 times by weight or more of the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent. Furthermore, in the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 10 times by weight or less, 12 times by weight or less, 13 times by weight or less, 14 times by weight or less, 15 times by weight or less, 20 times by weight or less, 25 times by weight or less, 30 times by weight or less, 35 times by weight or less, 40 times by weight or less, 45 times by weight or less, 50 times by weight or less, 60 times by weight or less, 70 times by weight or less, 80 times by weight or less, 90 times by weight or less, 100 times by weight or less, 150 times by weight or less, or 200 times by weight or less of the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent.

[0121] The above numerical values ​​can be freely combined. For example, in the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 2.6 to 200 times by weight, 2.8 to 150 times by weight, 3 to 100 times by weight, 3 to 30 times by weight, 5 to 30 times by weight, or 5 to 10 times by weight, the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent.

[0122] In the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 2.6 molar equivalents or more, 2.7 molar equivalents or more, 2.8 molar equivalents or more, 2.9 molar equivalents or more, 3 molar equivalents or more, 4 molar equivalents or more, 5 molar equivalents or more, 6 molar equivalents or more, 7 molar equivalents or more, 8 molar equivalents or more, or 9 molar equivalents or more of the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent. Furthermore, in the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 10 molar equivalents or less, 12 molar equivalents or less, 13 molar equivalents or less, 14 molar equivalents or less, 15 molar equivalents or less, 20 molar equivalents or less, 25 molar equivalents or less, 30 molar equivalents or less, 35 molar equivalents or less, 40 molar equivalents or less, 45 molar equivalents or less, 50 molar equivalents or less, 60 molar equivalents or less, 70 molar equivalents or less, 80 molar equivalents or less, 90 molar equivalents or less, 100 molar equivalents or less, 150 molar equivalents or less, or 200 molar equivalents or less of the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent.

[0123] The above numerical values ​​can be freely combined. For example, in the DUPAN-2 antigen measurement kit of the present disclosure, the amount of the first antibody that recognizes the DUPAN-2 antigen in the first reagent may be 2.6 to 200 molar equivalents, 2.8 to 150 molar equivalents, 3 to 100 molar equivalents, 3 to 30 molar equivalents, 5 to 30 molar equivalents, or 5 to 10 molar equivalents, relative to the amount of the second antibody that recognizes the DUPAN-2 antigen in the second reagent.

[0124] The concentration of the insoluble carrier in the first reagent may be 0.001 mg / mL or more, 0.01 mg / mL or more, 0.02 mg / mL or more, 0.03 mg / mL or more, 0.04 mg / mL or more, 0.05 mg / mL or more, 0.06 mg / mL or more, 0.07 mg / mL or more, 0.08 mg / mL or more, 0.09 mg / mL or more, 0.1 mg / mL or more, 0.2 mg / mL or more, 0.3 mg / mL or more, 0.4 mg / mL or more, or 0.5 mg / mL or more. In addition, the concentration of the insoluble carrier in the first reagent may be 0.6 mg / mL or less, 0.7 mg / mL or less, 0.8 mg / mL or less, 0.9 mg / mL or less, 1 mg / mL or less, 2 mg / mL or less, 3 mg / mL or less, 4 mg / mL or less, 5 mg / mL or less, 6 mg / mL or less, 7 mg / mL or less, 8 mg / mL or less, 9 mg / mL or less, or 10 mg / mL or less.

[0125] The above values ​​can be freely combined. For example, the concentration of the insoluble carrier in the first reagent may be 0.01 mg / mL to 10 mg / mL, 0.03 mg / mL to 5 mg / mL, or 0.1 mg / mL to 2 mg / mL.

[0126] The concentration of the first antibody recognizing the DUPAN-2 antigen in the first reagent is 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, It may be 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. Furthermore, the concentration of the first antibody that binds to the DUPAN-2 antigen in the first reagent may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0127] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen in the first reagent may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0128] In the first reagent, when the first antibody recognizing the DUPAN-2 antigen is bound to a microtiter plate and does not contain an aqueous medium and is in a dry state, the amount of the first antibody recognizing the DUPAN-2 antigen in one well of the microtiter plate may be 0.001 μg or more, 0.01 μg or more, 0.02 μg or more, 0.03 μg or more, 0.04 μg or more, 0.05 μg or more, 0.06 μg or more, 0.07 μg or more, 0.08 μg or more, 0.09 μg or more, 0.1 μg or more, 0.2 μg or more, 0.3 μg or more, 0.4 μg or more, or 0.5 μg or more. Furthermore, the amount of the first antibody that recognizes the DUPAN-2 antigen in one well of the microtiter plate may be 0.6 μg or less, 0.7 μg or less, 0.8 μg or less, 0.9 μg or less, 1 μg or less, 2 μg or less, 3 μg or less, 4 μg or less, 5 μg or less, 6 μg or less, 7 μg or less, 7.5 μg or less, 8 μg or less, 9 μg or less, 10 μg or less, 11 μg or less, 12 μg or less, 13 μg or less, 14 μg or less, 15 μg or less, 16 μg or less, 17 μg or less, 18 μg or less, 19 μg or less, 20 μg or less, 30 μg or less, 40 μg or less, 50 μg or less, or 100 μg or less.

[0129] The above values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen in one well of the microtiter plate may be 0.01 μg to 30 μg, 0.1 μg to 10 μg, or 0.3 μg to 3 μg.

[0130] The concentration of the second antibody recognizing the DUPAN-2 antigen in the second reagent may be 0.001 μg / mL or more, 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more, 0.33 μg / mL or more, 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, or 0.9 μg / mL or more. In addition, the concentration of the second antibody that binds to the DUPAN-2 antigen in the second reagent may be 1 μg / mL or less, 2 μg / mL or less, 3 μg / mL or less, 4 μg / mL or less, 5 μg / mL or less, 6 μg / mL or less, 7 μg / mL or less, 7.5 μg / mL or less, 8 μg / mL or less, 9 μg / mL or less, 10 μg / mL or less, 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0131] The above values ​​can be freely combined. For example, the concentration of the second antibody that binds to the DUPAN-2 antigen in the second reagent may be 0.01 μg / mL to 100 μg / mL, 0.03 μg / mL to 30 μg / mL, 0.1 μg / mL to 20 μg / mL, or 0.1 μg / mL to 1 μg / mL.

[0132] The constituent reagents of the measurement kit of the present disclosure may be in a lyophilized state or in liquid form. When the reagents constituting the assay kit are in a freeze-dried state, they are dissolved in an aqueous medium before assay to form a liquid, which is then used for assay. Examples of the aqueous medium include the aqueous media described above. The aqueous medium may contain the aforementioned salts, metal ions, sugars, proteins, surfactants, etc.

[0133] When the reagent components of the assay kit are liquid, at least one selected from the group consisting of an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen is dissolved in an aqueous medium. Examples of the aqueous medium include the aqueous media described above. The aqueous medium may contain the salts, metal ions, sugars, proteins, surfactants, etc. described above.

[0134] Examples of DUPAN-2 antigen of known concentration as a standard substance include a DUPAN-2 antigen solution obtained by diluting DUPAN-2 antigen derived from ascites fluid or DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF with PBS. The kit of the present disclosure may contain multiple DUPAN-2 antigens of known concentrations.

[0135] The concentration of DUPAN-2 antigen in the DUPAN-2 antigen of known concentration used as the standard substance may be, for example, the concentrations mentioned above.

[0136] "Method for producing an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen" The insoluble carrier having the first antibody that recognizes the DUPAN-2 antigen bound thereto, which is included in the measurement reagent and measurement kit of the present disclosure, can be produced by a method including the following steps. (1) adding an aqueous medium containing a first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier; and (2) A step of binding a first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier.

[0137] Methods for binding the first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier include, for example, the methods described above.

[0138] The concentration of the insoluble carrier in step (1) may be 0.001 mg / mL or more, 0.01 mg / mL or more, 0.02 mg / mL or more, 0.03 mg / mL or more, 0.04 mg / mL or more, 0.05 mg / mL or more, 0.06 mg / mL or more, 0.07 mg / mL or more, 0.08 mg / mL or more, 0.09 mg / mL or more, 0.1 mg / mL or more, 0.2 mg / mL or more, 0.3 mg / mL or more, 0.4 mg / mL or more, or 0.5 mg / mL or more. Furthermore, the concentration of the insoluble carrier in step (1) may be 0.6 mg / mL or less, 0.7 mg / mL or less, 0.8 mg / mL or less, 0.9 mg / mL or less, 1 mg / mL or less, 2 mg / mL or less, 3 mg / mL or less, 4 mg / mL or less, 5 mg / mL or less, 6 mg / mL or less, 7 mg / mL or less, 8 mg / mL or less, 9 mg / mL or less, or 10 mg / mL or less.

[0139] The above values ​​can be freely combined. For example, the concentration of the insoluble carrier in step (1) may be 0.01 mg / mL to 10 mg / mL, 0.03 mg / mL to 5 mg / mL, or 0.1 mg / mL to 2 mg / mL.

[0140] The amount of the first antibody that recognizes the DUPAN-2 antigen added in step (1) is not particularly limited, as long as it is an amount that enables the production of an insoluble carrier to which the first antibody that recognizes the DUPAN-2 antigen is bound, as disclosed herein. In step (1), the amount of the first antibody that recognizes the DUPAN-2 antigen added may be 0.5 ng or more, 1 ng or more, 1.5 ng or more, 2 ng or more, 2.5 ng or more, 3 ng or more, 3.5 ng or more, 4 ng or more, 4.5 ng or more, 5 ng or more, 10 ng or more, 15 ng or more, 20 ng or more, 25 ng or more, 30 ng or more, 35 ng or more, 40 ng or more, 45 ng or more, 50 ng or more, 100 ng or more, 150 ng or more, 200 ng or more, 250 ng or more, 300 ng or more, 350 ng or more, 400 ng or more, 450 ng or more, or 500 ng or more. Furthermore, the amount of the first antibody that recognizes the DUPAN-2 antigen added in step (1) may be 550 ng or less, 600 ng or less, 650 ng or less, 700 ng or less, 750 ng or less, 800 ng or less, 850 ng or less, 900 ng or less, 950 ng or less, 1 μg or less, 1.5 μg or less, 2 μg or less, 2.5 μg or less, or 5 μg or less.

[0141] The above values ​​can be freely combined. For example, the amount of the first antibody that recognizes the DUPAN-2 antigen added in step (1) may be 0.5 ng to 5 μg, 5 ng to 1.5 μg, 150 ng to 1 μg, 300 ng to 1 μg, or 500 ng to 1 μg.

[0142] The concentration of the first antibody that recognizes the DUPAN-2 antigen added in step (1) is not particularly limited as long as it is a concentration that enables the production of an insoluble carrier to which the first antibody that recognizes the DUPAN-2 antigen is bound, as disclosed herein. In the step (1), the concentration of the first antibody that binds to the DUPAN-2 antigen added is 0.01 μg / mL or more, 0.02 μg / mL or more, 0.03 μg / mL or more, 0.04 μg / mL or more, 0.05 μg / mL or more, 0.06 μg / mL or more, 0.07 μg / mL or more, 0.08 μg / mL or more, 0.09 μg / mL or more, 0.1 μg / mL or more, 0.2 μg / mL or more, 0.3 μg / mL or more. , 0.4 μg / mL or more, 0.5 μg / mL or more, 0.6 μg / mL or more, 0.7 μg / mL or more, 0.8 μg / mL or more, 0.9 μg / mL or more, 1 μg / mL or more, 2 μg / mL or more, 3 μg / mL or more, 4 μg / mL or more, 5 μg / mL or more, 6 μg / mL or more, 7 μg / mL or more, 7.5 μg / mL or more, 8 μg / mL or more, 9 μg / mL or more, or 10 μg / mL or more. Furthermore, in step (1), the concentration of the first antibody that binds to the DUPAN-2 antigen added may be 11 μg / mL or less, 12 μg / mL or less, 13 μg / mL or less, 14 μg / mL or less, 15 μg / mL or less, 16 μg / mL or less, 17 μg / mL or less, 18 μg / mL or less, 19 μg / mL or less, 20 μg / mL or less, 30 μg / mL or less, 40 μg / mL or less, 50 μg / mL or less, or 100 μg / mL or less.

[0143] The above values ​​can be freely combined. For example, the concentration of the first antibody that binds to the DUPAN-2 antigen added in step (1) may be 0.01 μg / mL to 100 μg / mL, 0.1 μg / mL to 30 μg / mL, 6 μg / mL to 30 μg / mL, or 10 μg / mL to 20 μg / mL.

[0144] The steps (1) and (2) are preferably carried out in an aqueous medium, such as the aqueous medium described above.

[0145] The temperature for the binding reaction in step (2) is not particularly limited as long as it allows for the method of producing an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen of the present disclosure, and is, for example, 0 to 50° C., preferably 4 to 45° C., and particularly preferably 20 to 40° C. The duration of the binding reaction in step (2) is also not particularly limited as long as it allows for the method of producing an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen, and is, for example, 5 minutes to 72 hours, preferably 10 minutes to 48 hours, more preferably 2 hours to 24 hours, and particularly preferably 12 hours to 18 hours. [Example]

[0146] The present disclosure will be described in more detail below with reference to examples, which are not intended to limit the scope of the present disclosure in any way. In the following examples, reagents from the following manufacturers were used.

[0147] The following reagents were used: disodium hydrogen phosphate (anhydrous) (Kanto Chemical Co., Ltd.), sodium dihydrogen phosphate (anhydrous) (Kanto Chemical Co., Ltd.), trishydroxymethylaminomethane (Kanto Chemical Co., Ltd.), sodium chloride (Fujifilm Wako Pure Chemical Industries, Ltd.), MES (Dojindo Laboratories, Ltd.), MOPS (Dojindo Laboratories, Ltd.), NP-40 (Sigma-Aldrich), Tween 20 (Kanto Chemical Co., Ltd.), Minimum Essential Medium Eagle (Sigma-Aldrich), fetal bovine serum (Thermo Fisher Scientific), bovine serum albumin (BSA) (Bovogen), and the "specimen diluent" component of "Determiner DUPAN-2 N" (Hitachi Chemical Diagnostic Systems Co., Ltd.).

[0148] [Example 1] Measurement kits 1 and 2 for DUPAN-2 antigen were prepared, each containing a DUPAN-2 antibody-conjugated microplate and a peroxidase (POD)-labeled DUPAN-2 antibody solution. When preparing the following DUPAN-2 antibody-conjugated microplates, the DUPAN-2 antibody solution with a DUPAN-2 antibody concentration of 10 μg / mL was used for measurement kit 1, and the one with a concentration of 20 μg / mL was used for measurement kit 2.

[0149] <DUPAN-2 antibody-conjugated microplate: primary antibody> To each well of a 96-well polystyrene plate (manufactured by Thermo Fisher Scientific), 50 μL of a DUPAN-2 antibody solution prepared with a binding buffer [0.01 mol / L phosphate buffer (pH 7.3) containing 0.14 mol / L sodium chloride] was added and incubated at 25 °C for 16 hours. Next, the DUPAN-2 antibody solution was removed, and 250 μL of a blocking solution [phosphate buffer (pH 7.2) containing 1% (w / v) BSA and 0.05% (w / v) Tween 20] was added to each well for washing. Then, 250 μL of the blocking solution was added to each well and incubated at 4 °C for 16 hours. After that, the blocking solution was removed, and a DUPAN-2 antibody-conjugated microplate was prepared.

[0150] <POD-labeled DUPAN-2 antibody solution: secondary antibody> Using a Peroxidase Labeling Kit-NH2 (manufactured by Dojindo Molecular Technologies, Inc.), according to the instruction manual of the kit, the DUPAN-2 antibody was labeled with POD to prepare a POD-labeled DUPAN-2 antibody. Using the obtained POD-labeled DUPAN-2 antibody, a POD-labeled DUPAN-2 antibody solution with the following composition was prepared.

[0151] MES (pH 6.5) 0.1 mol / L POD-labeled DUPAN-2 antibody 1 μg / mL BSA 0.1% (w / v) NP-40 0.2% (w / v) Sodium chloride 0.15 mol / L

[0152] [Comparative Example] A DUPAN-2 antibody-bound microplate was prepared using the above-described method for preparing a DUPAN-2 antibody-bound microplate, with the DUPAN-2 antibody concentration in the DUPAN-2 antibody solution set to 5 μg / mL. As a comparative example, Measurement Kit A was prepared by combining the DUPAN-2 antibody-bound microplate with the POD-labeled DUPAN-2 antibody solution prepared by the method described in Example 1.

[0153] [Example 2] <Method 1 for measuring DUPAN-2 in samples> Ascites-derived DUPAN-2 antigen solutions were prepared by adjusting the concentrations of DUPAN-2 antigen derived from the ascites of a human pancreatic cancer patient (hereinafter simply referred to as "ascites-derived DUPAN-2 antigen") in an antigen diluent [1% (w / v) BSA, 0.15 mol / L sodium chloride in 0.05 mol / L Tris buffer (pH 8.0)] to 40 U / mL, 100 U / mL, and 350 U / mL, respectively. Similarly, DUPAN-2 antigen derived from the culture supernatant of human pancreatic cancer cultured cell line HPAF-II was adjusted to 40 U / mL, 100 U / mL, and 350 U / mL in the same antigen diluent. Human pancreatic cancer cultured cells HPAF-II were cultured according to a known method (RS Metzgar et. al. CANCER RESEARCH (1982), 42 (2):601-608), and the culture supernatant obtained from the culture was used as DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF-II.

[0154] 100 μL of sample dilution was added to each well of the DUPAN-2 antibody-bound microplate. Then, 20 μL of DUPAN-2 antigen solution derived from ascites or DUPAN-2 antigen solution derived from human pancreatic cancer cultured cells HPAF-II was added to each well and incubated at 25°C for 1 hour (primary reaction). After the primary reaction, each well of the plate was washed with a washing solution [0.01 mol / L phosphate buffer (pH 7.4) containing 0.05% (w / v) Tween 20 and 0.15 mol / L sodium chloride], and then 100 μL of POD-labeled DUPAN-2 antibody solution was added to each well and incubated at 25°C for 1 hour (secondary reaction). After the secondary reaction, each well of the plate was washed with the washing solution. Then, 100 μL of TMB (3,3',5,5'-tetramethylbenzidine) aqueous solution was added to each well and incubated at 25°C for 30 minutes. 50 μL of 0.5 mol / L sulfuric acid was added to stop the reaction (color reaction). The absorbance (main wavelength 450 nm, secondary wavelength 650 nm) of the reaction solution obtained in the color reaction was measured using the microplate reader "Emax" (Molecular Devices Japan, Inc.). The absorbance measured with the DUPAN-2 antigen solution derived from ascites was defined as (A), and the absorbance measured with the DUPAN-2 antigen solution derived from human pancreatic cancer cultured cells HPAF-II was defined as (B). The (B) / (A) values ​​were calculated. The (B) / (A) values ​​are shown in Table 1.

[0155] Additionally, using Comparative Example Kit A, a DUPAN-2 antigen solution derived from ascites and a DUPAN-2 antigen solution derived from human pancreatic cancer cultured cells HPAF-II were measured according to Measurement Method 1 for DUPAN-2 in samples described in Example 2. The (B) / (A) values ​​were then calculated using the method described in Example 2. The (B) / (A) values ​​are shown in Table 1.

[0156] [Table 1] From the results in Table 1, the (B) / (A) values of Kit 1 and Kit 2 were close to 1.0. Kits 1 and 2 showing such (B) / (A) values had a tendency that the difference between the measured value of DUPAN-2 antigen derived from ascites and the measured value of DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF-II was smaller than that of Comparative Example Kit A, and it was found that accurate measurement could be performed.

[0157] [Example 3] A measurement kit 3 for DUPAN-2 antigen containing the following DUPAN-2 antibody-conjugated magnetic particle solution and alkaline phosphatase-labeled DUPAN-2 antibody solution was prepared.

[0158] <DUPAN-2 antibody-conjugated magnetic particle solution: Primary antibody> (1) Magnetic particle suspension As the magnetic particles, a commercially available magnetic particle conjugated with streptavidin [Dynabeads MyOne Streptavidin T1 (manufactured by Thermo Fisher Scientific)] was used to prepare a magnetic particle suspension having the following composition.

[0159] MES (pH 6.5) 50 mmol / L Streptavidin-conjugated magnetic particles 0.4 mg / mL BSA 0.1% (w / v) Sodium chloride 0.1 mol / L

[0160] (2) Biotin-conjugated DUPAN-2 antibody solution Using Biotin Labeling kit-NH2 (manufactured by Dojindo Molecular Technologies, Inc.), according to the instruction manual of the kit, a biotin-conjugated DUPAN-2 antibody in which biotin was conjugated to the DUPAN-2 antibody was prepared. Using the obtained biotin-conjugated DUPAN-2 antibody, a biotin-conjugated DUPAN-2 antibody solution having the following composition was prepared.

[0161] MES (pH 6.5) 50 mmol / L Biotin-conjugated DUPAN-2 antibody 7.μg / mL BSA 0.1% (w / v) Sodium chloride 0.1 mol / L

[0162] (3) DUPAN-2 antibody-bound magnetic particle liquid The magnetic particle suspension and the biotin-conjugated DUPAN-2 antibody solution were mixed in a 1:1 ratio and left to stand at 25°C for 16 hours to allow the magnetic particles to bind to the DUPAN-2 antibody. This solution was used as a DUPAN-2 antibody-conjugated magnetic particle solution.

[0163] <Alkaline phosphatase-labeled DUPAN-2 antibody solution: secondary antibody> Alkaline phosphatase-labeled DUPAN-2 antibody was prepared by conjugating alkaline phosphatase to the DUPAN-2 antibody using Alkaline Phosphatase Labeling kit-SH2 (Dojindo Laboratories, Inc.) according to the kit's instructions. Using the obtained alkaline phosphatase-labeled DUPAN-2 antibody, an alkaline phosphatase-labeled DUPAN-2 antibody solution with the following composition was prepared.

[0164] MES (pH 6.5) 50 mmol / L Alkaline phosphatase-labeled DUPAN-2 antibody 0.33 μg / mL BSA 0.1% (w / v) Sodium chloride 0.1 mol / L

[0165] [Example 4] <Method 2 for measuring DUPAN-2 in samples> The 350 U / mL ascites-derived DUPAN-2 antigen solution and the 350 U / mL human pancreatic cancer cultured cell HPAF-II-derived DUPAN-2 antigen solution prepared in Example 2 were used as measurement samples.

[0166] To 10 μL of the measurement sample, 60 μL of the DUPAN-2 antibody-conjugated magnetic particle solution prepared in Example 3 and 30 μL of the alkaline phosphatase-labeled DUPAN-2 antibody solution were added, stirred, and allowed to react for 20 minutes at 37°C. The magnetic particles were collected magnetically, and the reaction solution other than the magnetic particles was removed. The magnetic particles were then washed five times with a washing solution [50 mmol / L MOPS buffer (pH 7.35) containing 0.1% (w / v) Tween 20]. Next, 100 μL of a luminescent substrate solution containing 9-(4-chlorophenylthiophosphoryloxymethylidene)-10-methylacridan disodium salt as the main component was added and stirred. The amount of luminescence generated was measured using a fully automated chemiluminescence immunoassay system "CL-JACK NX" (Hitachi Chemical Diagnostics Systems Co., Ltd.). The luminescence intensity when measuring the DUPAN-2 antigen solution derived from ascites was defined as (A), and the luminescence intensity when measuring the DUPAN-2 antigen solution derived from human pancreatic cancer cultured cells HPAF-II was defined as (B). The (B) / (A) value was calculated. The (B) / (A) value is shown in Table 2.

[0167] Additionally, using Comparative Example Kit A, a DUPAN-2 antigen solution derived from ascites and a DUPAN-2 antigen solution derived from human pancreatic cancer cultured cells HPAF-II were measured according to Measurement Method 1 for DUPAN-2 in samples described in Example 2. The (B) / (A) values ​​were then calculated using the method described in Example 2. The (B) / (A) values ​​are shown in Table 2.

[0168] [Table 2]

[0169] The results in Table 2 show that the (B) / (A) value for Kit 3 was close to 1.0. Compared with Comparative Kit A, Kit 3, which exhibits such a (B) / (A) value, tends to have a smaller difference between the measured value of DUPAN-2 antigen derived from ascites and the measured value of DUPAN-2 antigen derived from human pancreatic cancer cultured cells HPAF-II, demonstrating that accurate measurements are possible. [Industrial Applicability]

[0170] The present disclosure provides a method, reagent, and kit for measuring DUPAN-2 antigen in a sample, which are effective and accurate for diagnosing cancers such as pancreatic cancer and biliary tract cancer.

Claims

1. preparing a mixture containing an aqueous medium, the DUPAN-2 antigen in the sample, a first antibody that recognizes the DUPAN-2 antigen and that is bound to an insoluble carrier, and a second antibody that recognizes the DUPAN-2 antigen; a method for measuring DUPAN-2 antigen in a sample, wherein the amount of the first antibody that recognizes the DUPAN-2 antigen in the mixed solution is 3 to 100 times by weight greater than the amount of the second antibody that recognizes the DUPAN-2 antigen.

2. (1) reacting a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier, with the DUPAN-2 antigen in a sample in an aqueous medium to form an immune complex on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (2) measuring the immune complex produced in step (1); Including, A method for measuring DUPAN-2 antigen in a sample, wherein the amount of the first antibody that recognizes the DUPAN-2 antigen in the reaction solution in step (1) is 3 to 100 times by weight the amount of the second antibody that recognizes the DUPAN-2 antigen.

3. (1) reacting a first antibody that recognizes the DUPAN-2 antigen, which is bound to an insoluble carrier, with the DUPAN-2 antigen in a sample in an aqueous medium to form an immune complex 1 on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen; (2) reacting a second antibody that recognizes the DUPAN-2 antigen with the immune complex 1 produced in step (1) in an aqueous medium to produce an immune complex 2 on the insoluble carrier, the immune complex 2 comprising the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (3) measuring the immune complex 2 produced in step (2); Including, A method for measuring DUPAN-2 antigen in a sample, wherein in step (2), the amount of the first antibody that recognizes the DUPAN-2 antigen is 3 to 100 times by weight the amount of the second antibody that recognizes the DUPAN-2 antigen.

4. (1) adding a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to an insoluble carrier, to a sample containing the DUPAN-2 antigen; (2) reacting the DUPAN-2 antigen with a first antibody that recognizes the DUPAN-2 antigen and a second antibody that recognizes the DUPAN-2 antigen, both of which are bound to the insoluble carrier, in an aqueous medium to form an immune complex on the insoluble carrier, which consists of the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (3) measuring the immune complex produced in step (2); Including, A method for measuring DUPAN-2 antigen in a sample, wherein in step (1), the amount of the first antibody that recognizes the DUPAN-2 antigen added is 3 to 100 times by weight the amount of the second antibody that recognizes the DUPAN-2 antigen added.

5. (1) adding a first antibody that recognizes the DUPAN-2 antigen, which is bound to an insoluble carrier, to a sample containing the DUPAN-2 antigen; (2) reacting the DUPAN-2 antigen with a first antibody that recognizes the DUPAN-2 antigen and that is bound to the insoluble carrier in an aqueous medium to form an immune complex 1 on the insoluble carrier, the immune complex 1 consisting of the first antibody that recognizes the DUPAN-2 antigen and the DUPAN-2 antigen; (3) adding a second antibody that recognizes the DUPAN-2 antigen to the immune complex 1 produced in step (2); (4) reacting a second antibody that recognizes the DUPAN-2 antigen with the immune complex 1 produced in step (2) in an aqueous medium to produce an immune complex 2 on the insoluble carrier, the immune complex 2 comprising the first antibody that recognizes the DUPAN-2 antigen, the DUPAN-2 antigen, and the second antibody that recognizes the DUPAN-2 antigen; and (5) measuring the immune complex 2 produced in step (4); Including, A method for measuring DUPAN-2 antigen in a sample, wherein the amount of a first antibody that recognizes the DUPAN-2 antigen added in step (1) is 3 to 100 times (by weight) the amount of a second antibody that recognizes the DUPAN-2 antigen added in step (3).

6. The method according to any one of claims 1 to 5, wherein a label is bound to the second antibody that recognizes the DUPAN-2 antigen.

7. The method of claim 6, wherein the label is alkaline phosphatase.

8. The antibody comprises an insoluble carrier to which a first antibody that recognizes the DUPAN-2 antigen is bound, and a second antibody that recognizes the DUPAN-2 antigen, A reagent for measuring DUPAN-2 antigen in a sample, wherein the amount of a first antibody that recognizes the DUPAN-2 antigen is 3 to 100 times by weight the amount of a second antibody that recognizes the DUPAN-2 antigen.

9. a first reagent containing an insoluble carrier bound to a first antibody that recognizes the DUPAN-2 antigen; and a second reagent containing a second antibody that recognizes the DUPAN-2 antigen, A kit for measuring DUPAN-2 antigen in a sample, wherein the amount of a first antibody that recognizes the DUPAN-2 antigen in a first reagent is 3 to 100 times by weight greater than the amount of a second antibody that recognizes the DUPAN-2 antigen in a second reagent.

10. A method for producing an insoluble carrier having a first antibody that recognizes the DUPAN-2 antigen bound thereto in the reagent according to claim 8, comprising the steps of: (1) adding an aqueous medium containing a first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier; and (2) binding a first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier; A method comprising:

11. The method according to claim 10, wherein in the step (1), the first antibody that recognizes the DUPAN-2 antigen is added at a concentration of 6 μg / mL or more and 30 μg / mL or less.

12. A method for producing an insoluble carrier having a first antibody that recognizes the DUPAN-2 antigen bound thereto in the kit according to claim 9, comprising: (1) adding an aqueous medium containing a first antibody that recognizes the DUPAN-2 antigen to an insoluble carrier; and (2) binding a first antibody that recognizes the DUPAN-2 antigen to the insoluble carrier; A method comprising:

13. The method according to claim 12, wherein in the step (1), the first antibody that recognizes the DUPAN-2 antigen is added at a concentration of 6 μg / mL or more and 30 μg / mL or less.

Images